Ahmet Eftal Yücel

Ahmet Eftal Yücel

Auto-generated profile, based on publicly available information

Ahmet Eftal Yücel

BAŞKENT ÜNİVERSİTESİ, TIP FAKÜLTES

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 December 2017 in Turkish Journal of Ophthalmology
Verified
Journal Article
Open access
OGOnur Gökmen
Onur Gökmen
Nilufer YesilirmakNilufer Yesilirmak
Nilufer Yesilirmak
AAAhmet Akman
Ahmet Akman
SGSirel Gür Güngör
Sirel Gür Güngör
AYAhmet Eftal Yücel
Ahmet Eftal Yücel
VDVasilios F Diakonis
Vasilios F Diakonis
To investigate corneal, scleral, choroidal, and foveal thicknesses in female patients with rheumatoid arthritis (RA) and compare them with healthy subjects. This prospective study included consecutive female patients diagnosed with RA and healthy subjects. Corneal, scleral, choroidal, and retinal (foveal) thicknesses were obtained by using optical coherence tomography and a comparison was performed between groups for all outcome measures. Thirty-six eyes of 36 female patients diagnosed with RA (group 1) and 36 eyes of 36 healthy female volunteers (group 2) were included. Mean corneal, scleral, choroidal thicknesses and retinal thickness at the fovea of group 1 were 543.3±33.7 µm, 343.7±42.2 µm, 214.6±50, and 213.5±18.9 µm, respectively; in group 2, these values were 549.9±29.6 μm, 420.9±42.4 μm, 206.4±41.9 μm, and 222±15.5 μm, respectively. The comparison between group 1 and 2 with respect to corneal, choroidal, and foveal thicknesses did not reveal statistical significant differences (p>0.05). On the contrary, there was a statistically significant difference with respect to scleral thickness between the groups, with the RA patients demonstrating a thinner scleral layer (p<0.001). Female patients with RA seem to demonstrate statistically significant scleral thinning when compared with healthy subjects, while there was no difference concerning corneal, choroidal, and foveal thickness.

30 August 2021 in TURKISH JOURNAL OF MEDICAL SCIENCES
Verified
Journal Article
Open access
MTMüge Aydin Tufan
Müge Aydin Tufan
NTNihan Tekkarişmaz
Nihan Tekkarişmaz
AYAhmet Eftal Yücel
Ahmet Eftal Yücel
Background This study aimed to determine the frequency of relapse, the risk factors for relapse, and the correlation of relapse with immunosuppressive regimens in patients with granulomatosis polyangiitis (GPA). Method The demographic characteristics, the clinical, laboratory, and radiological findings, the immunosuppressive treatment regimens, and the remission and relapse rates of 50 patients with GPA were obtained retrospectively from medical records. Results The mean relapse-free survival rates at years1, 3, and 5 were 82%, 60%, and 50%, respectively. Increased relapse rates were observed in patients who had cavitary lung lesions (52.2% vs. 22.2%, p=0.04) and in those who had elevated serum creatinine levels (1.8 vs. 0.9, p=0.00). The patients received two different types of remission induction therapies;36% of them received the combination therapy involving cyclophosphamide (CYC) and rituximab (RTX) and 62% received CYC alone. Relapse was observed in 22.3% of the patients who received the combination remission induction therapy and in 61.3% of the patients who received CYC alone (p=0.003). Conclusion An increased risk of relapse was observed in patients who had cavitary lung lesions and in those who had elevated serum creatinine levels. The combined use of RTX and CYC for the remission therapy in GPA reduced the relapse rates compared with the use of CYC alone.

31 March 2023 in Ulusal Romatoloji Dergisi
Verified
Journal Article
Closed access
BBBerivan Bitik
Berivan Bitik
MTMehmet Engin Tezcan
Mehmet Engin Tezcan
AYAhmet Eftal Yücel
Ahmet Eftal Yücel

30 September 2021 in Cukurova Medical Journal
Verified
Journal Article
Open access
PDF file
MTMüge Aydin Tufan
Müge Aydin Tufan
EBEmine Ersözlü Bozkirli
Emine Ersözlü Bozkirli
HKHamide Kart
Hamide Kart
AYAhmet Yücel
Ahmet Yücel
Amaç: Metotreksat (MTX), romatoid artrit (RA) için hala ana tedavi seçeneğidir. Tek başına veya diğer ilaçlarla kombinasyon halinde uygulandığında ilaç uygulama yolları ve dozajı konusunda fikir birliği yoktur. Bu çalışma, RA yönetiminde erken dönemde yüksek doz subkutan (SC) MTX içeren bir kombinasyon tedavisinin etkinliğini belirlemeyi amaçlamaktadır. Gereç ve Yöntem: Yeni tanı almış kırk beş RA’lı hasta rastgele iki gruba ayrıldı. İlk 4 haftada, haftada 12,5 mg SC MTX alan hastalar "düşük doz grubu" olarak tanımlandı. İlk 4 haftada, haftada 25 mg SC MTX alan hastalar "yüksek doz grubu" olarak tanımlandı. Daha sonra her iki gruptaki hastalar haftada 12.5 mg oral MTX ile devam etti. Hastalara ait başlangıç, 3. ay ve 6. ay klinik ve laboratuvar bulguları, hastalık aktivite skorları ve yanıt oranları kaydedildi. Bulgular: İki grup arasında 3. ay bulguları açısından anlamlı bir fark yoktu. 6. Ay değerleri açısından istatistiksel olarak anlamlı değişiklikler saptandı. Değerler düşük ve yüksek doz gruplarında şu şekildeydi: ortalama DAS28-CRP (3.5'e karşı 2.7; p = 0.01), VAS ağrı skoru (3.3'e karşı 1.6; p = 0.02) ve TJC28 (3'e karşı 1.5; p = 0.04), sırasıyla. Sonuç: Bu çalışma, erken dönemde yüksek doz SC MTX uygulamasının, hastalık aktivitesini etkili bir şekilde kontrol ettiğini ve RA hastalarında yaşam kalitesini arttırdığını göstermiştir. Purpose: Methotrexate (MTX) is still the main treatment option for rheumatoid arthritis (RA). There is no consensus on drug administration routes and dosage when administered alone or in combination with other drugs. This study aims to identify the effects of early administration of a combination therapy containing high dose subcutaneous (SC) MTX on RA management. Materials and Methods: Forty-five patients with RA who newly diagnosed were divided into two groups randomly. The patients who took 12.5 mg SC MTX per week in the first 4 weeks defined as a "low dose group". The patients who took 25 mg SC MTX per week in the first 4 weeks defined as a "high dose group". Then, patients of both groups continued with 12.5 mg oral MTX per week. Clinical and laboratory findings, disease activity scores and response rates of the patients were recorded at the beginning, 3rd months and 6th months. Results: There was no significant difference between the two groups at 3rd month’s values. There were statistically significant improvements at 6th month’s values. Values were as follows in low and high dose groups: mean DAS28-CRP (3.5 vs 2.7), VAS pain score (3.3 vs 1.6), and TJC28 (3 vs 1.5), respectively. Conclusion: Early administration of high-dose SC MTX effectively controls disease activity and increases the quality of life in RA patients.

30 April 2023 in Ankara Eğitim ve Araştırma Hastanesi Tıp Dergisi
Verified
Journal Article
Closed access
UÖUğur Özdemir
Uğur Özdemir
DKDerya Kaşkari̇
Derya Kaşkari̇
AYAhmet Eftal Yücel
Ahmet Eftal Yücel
Objectives: Destructive spondyloarthropathy (dSpA) occurs due to inflammatory destruction of axial joints due to beta2-microglobulin (beta2-M) accumulation in patients with end-stage renal disease (ESRD) receiving renal replacement therapy (RRT). This study aimed to investigate the frequency of dSpA in ESRD patients receiving RRT, by the diagnostic criteria sets of inflammatory back pain (IBP) and inflammatory classical SpA. Methods: A total of 140 patients were included. The data of the demographic informations, laboratory tests, clinical findings, HLA allele subgroups were collected. Sacroiliac and lateral feet X-rays and if necessary sacroiliac tomography were taken in patients with dSpA related pain. dSpA was investigated according to the Amor and ESSG criteria sets. Results: Fifty two patients were women (37%). The mean age was 51 ± 15 years. IBP and sacroiliitis were detected in 22 and 28 of the patients, respectively. There was a significant difference according to sacroiliitis and IBP in terms of CRP (p=0.028, p=0.043). dSpA were detected in 21 (15%) patients. Presence of HLA-A1 and duration of HD were determined as independent risk factors for dSpA. Conclusions: In the diagnosis of dSpA, the character and inflammatory origin of the pain and inflammatory markers should be investigated in addition to the radiological criteria.